Viale Pamela Hallquist, Sanchez Yamamoto Deanna
Clin J Oncol Nurs. 2003 Jul-Aug;7(4):393-401. doi: 10.1188/03.CJON.393-401.
Bisphosphonates are important inhibitors of osteoclastic bone resorption seen in patients with bone metastases associated with malignancy. Bisphosphonates are used in the treatment of patients with bone metastases and have been shown to reduce skeletal-related events and symptoms, contributing to improved patient outcomes and quality of life. These agents first were approved in the treatment of patients with osteoporosis and have been used for the past two decades in this role. Because bisphosphonates inhibit osteoclast-mediated bone resorption, the bone remodeling cycle slows down and an increase in bone mineral density occurs. These agents are useful in treatment for both hypercalcemia and pain, although they have not definitively shown improvement in survival time. Considerable interest exists in the use of bisphosphonates for prevention of bone metastases and their potential antitumor activity. These drugs are well tolerated and have minimal side effects, but they are not inexpensive. This article discusses the role of bisphosphonates in patients with cancer and future directions for further research.
双膦酸盐是恶性肿瘤相关骨转移患者中破骨细胞介导的骨吸收的重要抑制剂。双膦酸盐用于治疗骨转移患者，并已显示可减少骨相关事件和症状，有助于改善患者预后和生活质量。这些药物最初被批准用于治疗骨质疏松症患者，并在过去二十年中一直发挥着这一作用。由于双膦酸盐抑制破骨细胞介导的骨吸收，骨重塑周期减慢，骨矿物质密度增加。这些药物对高钙血症和疼痛的治疗均有用，尽管它们尚未明确显示能延长生存时间。人们对使用双膦酸盐预防骨转移及其潜在的抗肿瘤活性有着浓厚兴趣。这些药物耐受性良好，副作用极小，但价格并不便宜。本文讨论了双膦酸盐在癌症患者中的作用以及进一步研究的未来方向。
